Drug Index


Mechanism :

Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.

Indication :

  • Generalized anxiety disorder

Contraindications :

Contraindicated in patients with a known hypersensitivity to duloxetine or any of the inactive ingredients, in patients taking monoamine oxidase inhibitors (MAOIs) and in patients with uncontrolled narrow-angle glaucoma. It is not recommended in children less than 18 years.

Dosing :

Under 7 years:
Safety and efficacy not established.
7 to 17 years:
30 mg orally daily. After 2 weeks, dose can be increased to 60 mg/day. Max dose: 120 mg/day.

Adverse Effect :

Nausea, vomiting, dry mouth, fatigue, dizziness, anaphylactic reaction, edema, angioneurotic hypersensitivity, seizures upon treatment discontinuance, restless legs syndrome, extrapyramidal disorders, somnolence, galactorrhea, hyperglycemia, gynecologic bleeding, hyperprolactinemia, hypertensive crisis, supraventricular arrhythmia, glaucoma, aggression, anger, hallucinations, tinnitus, trismus, muscle spasm, erythema multiforme, Stevens-Johnson syndrome, urticaria, rash.

Interaction :

CNS Acting Drugs: It should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action.
Serotonergic Drugs: Caution is advised when duloxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid
Triptan: There have been rare post marketing reports of serotonin syndrome with use of an SSRI and a triptan.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
30-50Dose as in normal renal function; start with a low dose
10-30Start at low dose and increase according to response
<10Start at very low dose and increase according to response

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in GFR <10 mL/min
HDNot dialysed. Dose as in GFR <10 mL/min
HDF/High fluxUnlikely to be dialysed. Dose as in GFR <10 mL/min
CAV/VVHDNot dialysed. Dose as in GFR =10–30 mL/min

Hepatic Dose :

Do not use in chronic hepatic disease or cirrhosis.
02/14/2024 22:20:23 Duloxetine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0